Question : How Should I Monitor and Adjust the Clozapine Dose for My Patients Who Develop COVID and Could Benefit From Nirmatrelvir/Ritonavir?
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Journal of clinical psychopharmacology - 44(2024), 2 vom: 29. März, Seite 201-203 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Leon, Jose [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7R9A5P7H32 |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 04.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/JCP.0000000000001828 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36911843X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36911843X | ||
| 003 | DE-627 | ||
| 005 | 20240304232655.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/JCP.0000000000001828 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM36911843X | ||
| 035 | |a (NLM)38421928 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Leon, Jose |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Question |b How Should I Monitor and Adjust the Clozapine Dose for My Patients Who Develop COVID and Could Benefit From Nirmatrelvir/Ritonavir? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a nirmatrelvir |2 NLM | |
| 650 | 7 | |a 7R9A5P7H32 |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Clozapine |2 NLM | |
| 650 | 7 | |a J60AR2IKIC |2 NLM | |
| 650 | 7 | |a Lactams |2 NLM | |
| 650 | 7 | |a Leucine |2 NLM | |
| 650 | 7 | |a GMW67QNF9C |2 NLM | |
| 650 | 7 | |a Nitriles |2 NLM | |
| 650 | 7 | |a Proline |2 NLM | |
| 650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical psychopharmacology |d 1993 |g 44(2024), 2 vom: 29. März, Seite 201-203 |w (DE-627)NLM012629219 |x 1533-712X |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2024 |g number:2 |g day:29 |g month:03 |g pages:201-203 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/JCP.0000000000001828 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2024 |e 2 |b 29 |c 03 |h 201-203 | ||